515.
Powles, T.,
et al.
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder
cancer. Nature, 2014. 515: 558.
516.
Rosenberg, J.E.,
et al.
Atezolizumab in patients with locally advanced and metastatic urothelial
carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-
arm, multicentre, phase 2 trial. Lancet, 2016. 387: 1909.
517.
Bellmunt, J.,
et al.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
N Engl J Med, 2017. 376: 1015.
518.
Sharma, P.,
et al.
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate
275): a multicentre, single-arm, phase 2 trial. Lancet Oncol, 2017. 18: 312.
75
MUSCLE-INVASIVE AND METASTATIC
BLADDER CANCER
- LIMITED UPDATE MARCH 2018
519.
Farina, M.S.,
et al.
Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Drugs, 2017. 77: 1077.
520.
Apolo, A.B.,
et al.
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With
Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.
J Clin Oncol, 2017. 35: 2117.
521.
Powles, T.,
et al.
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial
Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol, 2017. 3: e172411.
522.
Youssef, R.F.,
et al.
Molecular targets and targeted therapies in bladder cancer management.
World J Urol, 2009. 27: 9.
523.
Shariat, S.F.,
et al.
Association of angiogenesis related markers with bladder cancer outcomes and
other molecular markers. J Urol, 2010. 183: 1744.
524.
Song, S.,
et al.
Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to
anticancer drugs. Proc Natl Acad Sci U S A, 2000. 97: 8658.
525.
Gomez-Roman, J.J.,
et al.
Fibroblast growth factor receptor 3 is overexpressed in urinary tract
carcinomas and modulates the neoplastic cell growth. Clin Cancer Res, 2005. 11: 459.
526.
Ioachim, E.,
et al.
Thrombospondin-1 expression in urothelial carcinoma: prognostic significance
and association with p53 alterations, tumour angiogenesis and extracellular matrix components.
BMC Cancer, 2006. 6: 140.
527.
Gallagher, D.J.,
et al.
Detection of circulating tumor cells in patients with urothelial cancer.
Ann Oncol, 2009. 20: 305.
528.
Flaig, T.W.,
et al.
Detection of circulating tumor cells in metastatic and clinically localized urothelial
carcinoma. Urology, 2011. 78: 863.
529.
Hoffmann, A.C.,
et al.
MDR1 and ERCC1 expression predict outcome of patients with locally
advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia, 2010. 12: 628.
You've reached the end of your free preview.
Want to read all 78 pages?
- Fall '18
- The American, bladder cancer
